Actively Recruiting
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Led by Chinese PLA General Hospital · Updated on 2023-06-05
2000
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
Sponsors
C
Chinese PLA General Hospital
Lead Sponsor
B
Beijing Municipal Science & Technology Commission
Collaborating Sponsor
AI-Summary
What this Trial Is About
Diabetes nephropathy (DN) is one of the most serious microvascular complications of diabetes, and also an important cause of death and disability of diabetes patients. There is no specific clinical staging of type 2 diabetes nephropathy at home and abroad, and there is no comprehensive study to comprehensively describe the occurrence and development of type 2 diabetes nephropathy through sensitive biomarkers, microvascular disease imaging and functional detection, digital markers and other multi-dimensional diagnosis and evaluation methods. Therefore, our research aims to establish a long-term follow-up queue for the whole cycle of diabetes nephropathy, develop multi-dimensional diagnostic and progress digital markers for diabetes nephropathy, develop a multimodal non-invasive diagnostic model and a new clinical staging/typing, and create a multi-dimensional accurate diagnosis and treatment system for type 2 diabetes nephropathy combining traditional Chinese and western medicine.
CONDITIONS
Official Title
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 18 years old, regardless of gender
- Diagnosis of type 2 diabetes
- Have a complete medical history and clinical data
- If type 2 diabetes patients have chronic kidney disease and underwent renal biopsy, the pathology diagnosis must be clear
- Patients voluntarily sign an informed consent form
You will not qualify if you...
- Incomplete medical history or clinical data
- Presence of hereditary kidney disease
- Current urinary tract infection
- Presence of autoimmune system diseases
- Diagnosis of malignant tumor with expected survival less than 6 months
- Pregnancy or lactation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, China, 100853
Actively Recruiting
Research Team
Z
Zheyi Dong, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here